MicroRNA-126 suppresses mesothelioma malignancy by targeting IRS1 and interfering with the mitochondrial function

Antioxidants and Redox Signaling

Volumn 21, Issue 15, 2014, Pages 2109-2125

  Tomasetti, Marco ^a   Nocchi, Linda ^a,b   Staffolani, Sara ^a   Manzella, Nicola ^a   Amati, Monica ^a   Goodwin, Jacob ^c   Kluckova, Katarina ^d   Nguyen, Maria ^c   Strafella, Elisabetta ^a   Bajzikova, Martina ^d   Peterka, Martin ^d   Lettlova, Sandra ^d   Truksa, Jaroslav ^d   Lee, Wan ^e   Dong, Lan Feng ^c   Santarelli, Lory ^a   Neuzil, Jiri ^c,d  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c GRIFFITH UNIVERSITY   (Australia)

^d INSTITUTE OF BIOTECHNOLOGY   (Czech Republic)

^e Dongguk University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE CITRATE SYNTHASE; CITRIC ACID; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INSULIN RECEPTOR SUBSTRATE 1; MICRORNA 126; MITOCHONDRIAL DNA; PROTEIN KINASE B; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROTENONE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOX01; UNCLASSIFIED DRUG; FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, HUMAN; HIF1A PROTEIN, HUMAN; INSULIN RECEPTOR SUBSTRATE; IRS1 PROTEIN, HUMAN; MICRORNA; MIRN126 MICRORNA, HUMAN;

ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL STRESS; CONTROLLED STUDY; ENERGY METABOLISM; ENZYME ACTIVATION; ENZYME REGULATION; GLUCONEOGENESIS; GLYCOLYSIS; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; MALIGNANT MESOTHELIOMA; MESOTHELIOMA CELL LINE; MITOCHONDRIAL DNA DEPLETION; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; RECEPTOR DOWN REGULATION; RNA ANALYSIS; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; CANCER TRANSPLANTATION; CELL HYPOXIA; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; MESOTHELIOMA; METABOLISM; NUDE MOUSE; OXYGEN CONSUMPTION; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

MUS MUSCULUS;

ANIMALS; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOLYSIS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INSULIN RECEPTOR SUBSTRATE PROTEINS; LUNG NEOPLASMS; MESOTHELIOMA; MICE, NUDE; MICRORNAS; MITOCHONDRIA; NEOPLASM TRANSPLANTATION; OXIDATIVE STRESS; OXYGEN CONSUMPTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 84928880532     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2013.5215     Document Type: Article

References (70)

1. Abu-Amero KK and Bosley TM. Detection of mitochondrial respiratory dysfunction in circulating lymphocytes using resazurin. Arch Pathol Lab Med 129: 1295-1298, 2005.
2. Atamna H, Nguyen A, Schultz C, Boyle K, Newberry J, Kato H, and Ames BN. Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. FASEB J 22: 703-712, 2008.
3. Baggetto LG. Deviant energetic metabolism of glycolytic cancer cells. Biochimie 74: 959-974, 1992.
4. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
5. Baserga R. The contradictions of the insulin-like growth factor 1 receptor. Oncogene 19: 5574-5581, 2000.
6. BauerDE, HatzivassiliouG, ZhaoF, AndreadisC, andThompson CB. ATP citrate lyase is an important component of cell growthandtransformation.Oncogene24:6314-6322, 2005.
7. Berridge MV, Herst PM, and Tan AS. Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnol Annu Rev 11: 127-152, 2005.
8. Busacca S, Germano S, De Cecco L, Rinaldi M, Comoglio F, Favero F, Murer B, Mutti L, Pierotti M, and Gaudino G. MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications. Am J Respir Cell Mol Biol 42: 312-319, 2010.
9. Cabeza-Arvelaiz Y and Schiestl RH. Transcriptome analysis of a rotenone model of parkinsonism reveals complex I-tied and-untied toxicity mechanisms common to neurodegenerative diseases. PLoS One 7: e44700, 2012.
10. Calin GA and Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866, 2006.
11. Croce CM and Calin GA. miRNAs, cancer, and stem cell division. Cell 122: 6-7, 2005.
12. Dong LF, Freeman R, Liu J, Zobalova R, Marin-Hernandez A, Stantic M, Rohlena J, Valis K, Rodriguez-Enriquez S, Butcher B, Goodwin J, Brunk UT, Witting PK, Moreno-Sanchez R, Scheffler IE, Ralph SJ, and Neuzil J. Suppression of tumour growth in vivo by the mitocan a-tocopheryl succinate requires respiratory complex II. Clin Cancer Res 15: 1593-1600, 2009.
13. Dong LF, Swettenham E, Eliasson J, Wang XF, Gold M, Medunic Y, Stantic M, Low P, Prochazka L, Witting PK, Turanek J, Akporiaye ET, Ralph SJ, and Neuzil J. Vitamin E analogs inhibit angiogenesis by selective apoptosis induction in proliferating endothelial cells: the role of oxidative stress. Cancer Res 67: 11906-11913, 2007.
14. Dong XC, Copps KD, Guo S, Li Y, Kollipara R, DePinho RA, and White MF. Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation. Cell Metab 8: 65-76, 2008.
15. Farh KK, Grimson A, Jan C, Lewis BP, Johnston WK, Lim LP, Burge CB, and Bartel DP. The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science 310: 1817-1821, 2005.
16. Feng R, Chen X, Yu Y, Su L, Yu B, Li J, Cai Q, Yan M, Liu B, and Zhu Z. miR-126 functions as a tumour suppressor in human gastric cancer. Cancer Lett 298: 50-63, 2010.
17. Fennell DA, Gaudino G, O'Byrne KJ, Mutti L, and van Meerbeeck J. Advances in the systemic therapy of malignant pleuralmesothelioma.NatClinPractOncol 5: 136-147, 2008.
18. Fiaschi T, Marini A, Giannoni E, Taddei ML, Gandellini P, De Donatis A, Lanciotti M, Serni S, Cirri P, and Chiarugi P. Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay. Cancer Res 72: 5130-5140, 2012.
19. Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, Ivey KN, Bruneau BG, Stainier DY, and Srivastava D. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 15:272-284, 2008.
20. Gameiro PA, Yang J, Metelo AM, Pérez-Carro R, Baker R, Wang Z, Arreola A, Rathmell WK, Olumi A, López-Larrubia P, Stephanopoulos G, and Iliopoulos O. In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell Metab 17: 372-385, 2013.
21. Gao P, Sun L, He X, Cao Y, and Zhang H. MicroRNAs and the Warburg Effect: new players in an old arena. Curr Gene Ther 12: 285-291, 2012.
22. GerlingerM, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, JonesD, Raine K, LatimerC, SantosCR, NohadaniM, Eklund AC, Spencer-DeneB, Clark G, PickeringL, StampG, GoreM, Szallasi Z, Downward J, Futreal PA, and Swanton C. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366: 883-892, 2012.
23. Guo C, Sah JF, Beard L, Willson JK, Markowitz SD, and Guda K. The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. Genes Chromosomes Cancer 47: 939-946, 2008.
24. Guo S, Copps KD, Dong X, Park S, Cheng Z, Pocai A, Rossetti L, Sajan M, Farese RV, and White MF. The Irs1 branch of the insulin signaling cascade plays a dominant role in hepatic nutrient homeostasis. Mol Cell Biol 29: 5070-5083, 2009.
25. Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D, Hingorani SR, Tuveson DA, and Thompson CB. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8: 311-321, 2005.
26. Hayden EC. Cancer complexity slows quest for cure. Nature 455: 158, 2008.
27. He J, Xu Q, Jing Y, Agani F, Qian X, Carpenter R, Li Q, Wang XR, Peiper SS, Lu Z, Liu LZ, and Jiang BH. Reactive oxygen species regulate ERBB2 and ERBB3 expression via miR-199a/125b and DNA methylation. EMBO Rep 13: 1116-1122, 2012.
28. Higuchi M, Manna SK, Sasaki R, and Aggarwal BB. Regulation of the activation of nuclear factor jB by mitochondrial respiratory function: evidence for the reactive oxygen species-dependent and-independent pathways. Antioxid Redox Signal 4: 945-955, 2002.
29. Hollevoet K, Reitsma JB, Creaney J, Grigoriu BD, Robinson BW, Scherpereel A, Cristaudo A, Pass HI, Nackaerts K, Rodr guez Portal JA, Schneider J, Muley T, Di Serio F, Baas P, Tomasetti M, Rai AJ, and van Meerbeeck JP. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol 30: 1541-1549, 2012.
30. Ivanov SV, Goparaju CM, Lopez P, Zavadil J, Toren-Haritan G, Rosenwald S, Hoshen M, Chajut A, Cohen D, and Pass HI. Pro-tumorigenic effects of miR-31 loss in mesothelioma. J Biol Chem 285: 22809-22817, 2010.
31. Kaplan RS, Mayor JA, and Wood DO. The mitochondrial tricarboxylate transport protein. cDNA cloning, primary structure, and comparison with other mitochondrial transport proteins. J Biol Chem 268: 13682-13690, 1993.
32. Keith B, Johnson RS, and Simon MC. HIF1a and HIF2a: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 12: 9-22, 2011.
33. Kops GJ, Dansen TB, Polderman PE, Saarloos I, Wirtz KW, Coffer PJ, Huang TT, Bos JL, Medema RH, and Burgering BM. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 419: 316-321, 2002.
34. Kubo T, Toyooka S, Tsukuda K, Sakaguchi M, Fukazawa T, Soh J, Asano H, Ueno T, Muraoka T, Yamamoto H, Nasu Y, Kishimoto T, Pass HI, Matsui H, Huh NH, and Miyoshi S. Epigenetic silencing of microRNA-34b/c plays an important role in the pathogenesis of malignant pleural mesothelioma. Clin Cancer Res 17: 4965-4974, 2011.
35. La Rocca G, Badin M, Shi B, Xu SQ, Deangelis T, Sepp-Lorenzinoi L, and Baserga R. Mechanism of growth inhi-bition by MicroRNA 145: the role of the IGF-I receptor signaling pathway. J Cell Physiol 220: 485-491, 2009.
36. Leung AK and Sharp PA. MicroRNA functions in stress responses. Mol Cell 40: 205-215, 2010.
37. Li P, Jiao J, Gao G, and Prabhakar BS. Control of mitochondrial activity by miRNAs. J Cell Biochem 113: 1104-1110, 2012.
38. Musiyenko A, Bitko V, and Barik S. Ectopic expression of miR-126, anintronicproduct ofthevascularendothelialEGFlike 7 gene, regulates protein translation and invasiveness of prostate cancerLNCaP cells. JMolMed 86: 313-322, 2008.
39. Nadege B, Patrick L, and Rodrigue R. Mitochondria: from bioenergetics to the metabolic regulation of carcinogenesis. Front Biosci 14: 4015-4034, 2009.
40. Nakashima RA, Paggi MG, and Pedersen PL. Contributions of glycolysis and oxidative phosphorylation to adenosine 5¢-triphosphate production in AS-30D hepatoma cells. Cancer Res 44: 5702-5706, 1984.
41. Nemoto S and Finkel T. Redox regulation of forkhead proteins through a p66shc-dependent signaling pathway. Science 295: 2450-1452, 2002.
42. Nocchi L, Tomasetti M, Amati M, Neuzil J, Santarelli L, and Saccucci S. Thrombomodulin is silenced in malignant mesothelioma by a poly(ADP-ribose)polymerase-1-mediated epigenetic mechanism. J Biol Chem 286: 19478-19488, 2011.
43. O'Hagan HM, Wang W, Sen S, Destefano Shields C, Lee SS, Zhang YW, Clements EG, Cai Y, Van Neste L, Easwaran H, Casero RA, Sears CL, and Baylin SB. Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. Cancer Cell 20: 606-619, 2011.
44. Pass HI, Goparaju C, Ivanov S, Donington J, Carbone M, Hoshen M, Cohen D, Chajut A, Rosenwald S, Dan H, Benjamin S, and Aharonov R. hsa-miR-29c is linked to the prognosis of malignant pleural mesothelioma. Cancer Res 70: 1916-1924, 2010.
45. Rasmussen AK, Chatterjee A, Rasmussen LJ, and Singh KK. Mitochondria-mediated nuclear mutator phenotype in Saccharomyces cerevisiae. Nucleic Acids Res 31: 3909-3917, 2003.
46. Ricci C, Pastukh V, Leonard J, Turrens J, Wilson G, Schaffer D, and Schaffer SW. Mitochondrial DNA damage triggers mitochondrial-superoxide generation and apoptosis. Am J Physiol Cell Physiol 294: C413-C422, 2008.
47. Rippo MR, Moretti S, Vescovi S, Tomasetti M, Orecchia S, Amici G, Catalano A, and Procopio A. FLIP overexpression inhibits death receptor-induced apoptosis in malignant mesothelial cells. Oncogene 23: 7753-7760, 2004.
48. Robinson BWS, Musk AW, and Lake AR. Malignant mesothelioma. Lancet 366: 397-408, 2005.
49. Ryu HS, Park SY, Ma D, Zhang J, and Lee W. The induction of microRNA targeting IRS-1 is involved in the development of insulin resistance under conditions of mitochondrial dysfunction in hepatocytes. PLoS One 6: e17343, 2011.
50. Sadagurski M, Cheng Z, Rozzo A, Palazzolo I, Kelley GR, Dong X, Krainc D, and White MF. IRS2 increases mitochondrial dysfunction and oxidative stress in a mouse model of Huntington disease. J Clin Invest 121: 4070-4081, 2011.
51. Saito Y, Friedman JM, Chihara Y, Egger G, Chuang JC, and LiangG. Epigenetic therapy upregulates the tumor suppressor microRNA-126 and its host gene EGFL7 in human cancer cells. Biochem Biophys Res Commun 379: 726-731, 2009.
52. Santarelli L, Strafella E, Staffolani S, Amati M, Emanuelli M, Sartini D, Pozzi V, Carbonari D, Bracci M, Pignotti E, Mazzanti P, Sabbatini A, Ranaldi R, Gasparini S, Neuzil J, and Tomasetti M. Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma. PLoS One 6: e18232, 2011.
53. Schetter AJ, Okayama H, and Harris CC. The role of microRNAs in colorectal cancer. Cancer J 18: 244-252, 2012.
54. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, Pan Y, Simon MC, Thompson CB, and Gottlieb E. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-a prolyl hydroxylase. Cancer Cell 7: 77-85, 2005.
55. Sotgia F, Martinez-Outschoorn UE, and Lisanti MP. Mitochondrial oxidative stress drives tumor progression and metastasis: should we use antioxidants as a key component of cancer treatment and prevention? BMC Med 9: 62, 2011.
56. Sotgia F, Whitaker-Menezes D, Martinez-Outschoorn UE, Salem AF, Tsirigos A, Lamb R, Sneddon S, Hulit J, Howell A, and Lisanti MP. Mitochondria "fuel" breast cancer metabolism: fifteen markers of mitochondrial biogenesis label epithelial cancer cells, but are excluded from adjacent stromal cells. Cell Cycle 11: 4390-4401, 2012.
57. Stapelberg M, Gellert N, Swettenham E, Tomasetti M, Witting PK, Procopio A, and Neuzil J. a-Tocopheryl succinate inhibits malignant mesothelioma by disrupting the FGF autocrine loop: the role of oxidative stress. J Biol Chem 280: 25369-25376, 2005.
58. Tavazoie SF, Alarcón C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, and Massagué J. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451: 147-152, 2008.
59. Tomasetti M, Gellert N, Procopio A, and Neuzil J. A vitamin E analogue suppresses malignant mesothelioma in a pre-clinical model: a prototype of a future drug against a fatal neoplastic disease? Int J Cancer 109: 641-642, 2004.
60. Tomasetti M, Staffolani S, Nocchi L, Neuzil J, Strafella E, Manzella N, Mariotti L, Bracci M, Valentino M, Amati M, and Santarelli L. Clinical significance of circulating miR-126 quantification in malignant mesothelioma patients. Clin Biochem 45: 575-581, 2012.
61. van de Loosdrecht AA, Beelen RH, Ossenkoppele GJ, Broekhoven MG, and Langenhuijsen MM. A tetrazoliumbased colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. J Immunol Methods 174: 311-320, 1994.
62. Wang M, Kirk JS, Venkataraman S, Domann FE, Zhang HJ, Schafer FQ, Flanagan SW, Weydert CJ, Spitz DR, Buettner GR, and Oberley LW. Manganese superoxide dismutase suppresses hypoxic induction of hypoxiainducible factor-1a and vascular endothelial growth factor. Oncogene 24: 8154-8166, 2005.
63. Wang X, Tang S, Le SY, Lu R, Rader JS, Meyers C, and Zheng ZM. Aberrant expression of oncogenic and tumorsuppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One 3: e2557, 2008.
64. Wang XF, Birringer M, Dong LF, Veprek P, Low P, Swettenham E, Stantic M, Yuan LH, Zobalova R, Wu K, Ledvina M, Ralph SJ, and Neuzil J. A peptide adduct of vitamin E succinate targets breast cancer cells with high erbB2 expression. Cancer Res 67: 3337-3344, 2007.
65. Ward PS and Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 21: 297-308, 2012.
66. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM, and Harris CC. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189-198, 2006.
67. Zhang J, Du YY, Lin YF, Chen YT, Yang L, Wang HJ, and Ma D. The cell growth suppressor, mir-126, targets IRS-1. Biochem Biophys Res Commun 377: 136-140, 2008.
68. Zhang W, Patil S, Chauhan B, Guo S, Powell DR, Le J, Klotsas A, Matika R, Xiao X, Franks R, Heidenreich KA, Sajan MP, Farese RV, Stolz DB, Tso P, and Koo SH. FoxO1 regulates multiple metabolic pathways in the liver: effects on gluconeogenic, glycolytic, and lipogenic gene expression. J Biol Chem 281: 10105-10117, 2006.
69. Zhang X, Tang N, Hadden TJ, and Rishi AK. Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta 1813: 1978-1986, 2011.
70. Zhu N, Zhang D, Xie H, Zhou Z, Chen H, Hu T, Bai Y, Shen Y, Yuan W, Jing Q, and Qin Y. Endothelial-specific intron-derived miR-126 is down-regulated in human breast cancer and targets both VEGFA and PIK3R2. Mol Cell Biochem 351: 157-164, 2011